A look at PHIO technical analysis shows that its 14-day Relative Strength Index (RSI) is in a neutral zone after reaching 60.95 point. Its trading volume has added 1284565 shares compared to readings over the past three months as it recently exchanged 1622145 shares. This means there is improved activity from short-term traders as per session, its average trading volume is 337580 shares, and this is 4.81 times the normal volume.
Phio Pharmaceuticals Corp. (NASDAQ:PHIO) climbed by 12.94% over the past three months which led to its overall six-month decrease to stand at -71.96%. The equity price rose 13.89% this week, a trend that has led to both investors and traders taking note of the stock. A look at its monthly performance shows that its shares have recorded a 12.63% gain over the past 30 days. Over the past 12 months the stock has embarked on a drop that has seen it decline -89.19% and is now up by 23.25% since start of this year.
The shares of Phio Pharmaceuticals Corp. dropped by -93.93% or -$6.35 from its last recorded high of $6.76 which it attained on March 15 to close at $0.41 per share. Over the past 52 weeks, the shares of Phio Pharmaceuticals Corp. has been trading as low as $0.27 before witnessing a massive surge by 51.85% or $0.14. This price movement has led to the PHIO stock receiving more attention and has become one to watch out for. It dipped by -5.44% on Wednesday and this got the market worried. The stock’s beta now stands at 1.97 and when compared to its 200-day moving average and its 50-day moving average, PHIO price stands -59.65% below and 12.6% above respectively. Its average daily volatility for this week is 7.09% which is more than the 4.83% recorded over the past month.
Experts from research firms are bullish about the near-term performance of Phio Pharmaceuticals Corp. (PHIO) with most of them predicting a $2 price target on a short-term (12 months) basis. The average price target by the analysts will see a 387.8% rise in the stock and would lead to PHIO’s market cap to surge to $35.68M. The stock has been rated an average 0, which roughly stands towards the bullish end of the spectrum. Reuters looked into the 1 analysts that track Phio Pharmaceuticals Corp. (NASDAQ:PHIO) and find out that 0 of them rated it as a Hold. 1 of the 1 analysts rated it as a Buy or a Strong Buy while 0 advised investors to desist from buying the stock or sell it if they already possess it.
The price of ZAGG Inc (NASDAQ:ZAGG) currently stands at $9.63 after it went down by $-1.2 or -11.08% and has found a strong support at $8.82 a share. If the ZAGG price drops below that critical support, then it would lead to a bearish trend. In the short-term, a dip below the $8 mark would also be bad for the stock as it means that the stock would plunge by 16.93% from its current position. However, if the stock price is able to trade above the resistance point around $10.68, then it could likely surge higher to try and break the upward resistance which stands at $11.73 a share. Its average daily volatility over the past one month stands at 4.02%. The stock has plunged by 5.99% from its 52-weeks high of $9.0532 which it reached on Jun. 27, 2018. In general, it is 17.34% above its 52-weeks lowest point which stands at $7.96 and this setback was observed on Dec. 24, 2018.
Analysts have predicted a price target for ZAGG Inc (ZAGG) for 1 year and it stands at an average $17.1/share. This means that it would likely increase by 77.57% from its current position. The current price of the stock has been moving between $9.0532 and $10.92. Some brokerage firms have a lower target for the stock than the average, with one of them setting a price target as low as $11. On the other hand, one analyst is super bullish about the price, setting a target as high as $24.
The ZAGG stock Stochastic Oscillator (%D) is at 18.43%, which means that it is currently oversold and its prices could jump very soon. The shares P/S ratio stands at 0.55 which compares to the 0.46 recorded by the industry or the 2.63 by the wider sector. The stock currently has an estimated price-earnings (P/E) multiple of 5.83, which is lower than the 6.12 multiple of 12-month price-earnings (P/E). The company’s earnings have gone up, with a quarterly increase rate of 16.1% over the past five years.
Analysts view ZAGG Inc (NASDAQ:ZAGG) as a Buy, with 0 consensus rating. Reuters surveyed 5 analysts that follow ZAGG and found that 2 of those analysts rated the stock as a Hold. The remaining 3 were divided, with 3 analyst rating it as a Buy or a Strong Buy while 0 analysts advised investors to desist from buying ZAGG Inc (ZAGG) shares or sell it if they already own it.
This post was originally published on *this site*